Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world study of foslevodopa/foscarbidopa implementation in advanced Parkinson's disease
NL-OMON61609Not yet recruiting
- Sponsor
- AbbVie Inc.
- Start
- Mar 2025
- Modality
- Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of foslevodopa and foscarbidopa in Parkinson's disease (PD), sponsored by AbbVie Inc. Primary endpoint: Evolution of infusion settings. Planned start Mar 2025; status: not yet recruiting.
02
Drugs
foslevodopafoscarbidopa
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NL-OMON61609.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61609.